Apogee Therapeutics

Apogee Therapeutics

Organization

Heard in 3 episodes across 1 show since Jun 2026

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of immunological and inflammatory disorders. The company's pipeline targets conditions with high unmet needs, including atopic dermatitis, chronic obstructive pulmonary disease (COPD), and asthma.

Episodes

3
across 1 show

First heard

Jun 2026

Expert statements

3
3 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20263
Jul 20260
Aug 20260
Sep 20260
Oct 20260
Nov 20260

Email alert

Email me when Apogee Therapeutics comes up on a podcast

One email a week at most, with the new episodes that mention Apogee Therapeutics. Free, no account needed, unsubscribe in one click.

What experts have said about Apogee Therapeutics

3 statements · 3 positive

  1. Nathan HagerPositiveJun 22, 2026· Stock Movers

    Apogee has a promising experimental psoriasis compound.

    “that company's got a promising experimental compound for psoriasis”

    Listen at 1:18

    Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
  2. Nathan HagerPositiveJun 22, 2026· Stock Movers

    Apogee’s psoriasis compound could rival Sanofi’s Dupixent.

    “it could be a rival to France's Sanofi and its blockbuster Dupixit”

    Listen at 1:25

    Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
  3. Dan CurtisPositiveJun 22, 2026· Stock Movers

    AbbVie is nearing an approximately $11 billion acquisition of Apogee.

    “AbbVie is closing in on a nearly $11 billion deal to buy Apogee.”

    Listen at 1:51

    Open the episode · Arcosa and Apogee Rise; Getty Jumps

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

3 episodes featuring Apogee Therapeutics, newest first